ADVFN - Advanced Financial Network.
HOME» NASDAQ » I » ILMN Stock Price » ILMN Stock News

Illumina Share News

 Illumina (mm) Stock Price
ILMN Stock Price
 Illumina (mm) Stock Chart
ILMN Stock Chart
 Illumina (mm) Stock News
ILMN Stock News
 Illumina (mm) Company Information
ILMN Company Information
 Illumina (mm) Stock Trades
ILMN Stock Trades

Two Proxy Advisory Firms Side With Illumina In Roche Fight

DOW JONES NEWSWIRES Two proxy advisory firms have recommended Illumina Inc. (ILMN) shareholders vote against Swiss drug maker Roche Holding AG's (ROG.VX, RHHBY) nominees to Illumina's board, calling its takeover offer inadequate. The proxy advisor reports comes as Illumina, a U.S. gene-sequencing company, fights to hold off a hostile bid from Roche. The report from Institutional Shareholder Services said shareholders should vote the Illumina board back into service, and reject Roche's slate because the offer likely undervalues the future of Illumina. Egan-Jones Ratings Co. made a similar call. ISS said the current bid doesn't offer "meaningful compensation for the potentially enormous long-term opportunity shareholders would forego by selling at this point." It also noted the lack of competition in the near future and the vast potential for sequencing. Roche expressed disappointment Friday in the report from ISS. "We respectfully challenge ISS' assertion that our current 'bid does not provide a compelling starting point for negotiations,'" Roche Chief Executive Severin Schwan said. "Our goal has always been to enter into a negotiated transaction with Illumina and we firmly believe that our present offer is more than adequate to serve as a basis for negotiation with Illumina." Schwan said that while the company is disappointed in ISS's recommendation against Roche's director nominees, the company is "pleased" that ISS notes Roche would be "an excellent partner for Illumina as the sequencing industry grows more intertwined with new drug development." Wednesday, Roche stepped up pressure on Illumina shareholders, telling them in a letter to tender their shares to Roche's increased offer and vote for its independent director nominees at the company's annual meeting later this month. Roche, which launched its hostile offer for Illumina in January, last week raised its offer for Illumina to $51 a share from $44.50. However, Roche's sweetened offer, which values Illumina at more than $6.5 billion, has been rejected by Illumina's board as still being too low. Illumina's stock closed at $52.33 Thursday. The stock is up 72% so far this year. -By Nathalie Tadena, Dow Jones Newswires; 212-416-3287; nathalie.tadena@dowjones.com

Stock News for Illumina (ILMN)
DateTimeHeadline
07/31/201517:30:46Statement of Changes in Beneficial Ownership (4)
07/31/201516:31:31Quarterly Report (10-q)
07/24/201519:36:07Statement of Changes in Beneficial Ownership (4)
07/24/201519:20:27Statement of Changes in Beneficial Ownership (4)
07/22/201508:31:44Current Report Filing (8-k)
07/21/201516:09:00Current Report Filing (8-k)
07/21/201516:05:00Illumina Reports Financial Results for Second Quarter of Fiscal...
07/20/201516:05:00Illumina Names Sanjay Chikarmane as Senior Vice President and...
07/17/201518:30:53Statement of Changes in Beneficial Ownership (4)
07/17/201517:21:19Statement of Changes in Beneficial Ownership (4)
07/16/201518:45:31Statement of Changes in Beneficial Ownership (4)
07/16/201518:31:26Statement of Changes in Beneficial Ownership (4)
07/16/201506:30:00Illumina Introduces Illumina SeqLab
07/15/201516:04:02Amended Annual Report (10-k/a)
07/13/201516:05:00Study of Illumina’s Non-Invasive verifi® Prenatal Test Suggests th...
07/10/201516:48:22Amended Statement of Changes in Beneficial Ownership (4/a)
07/07/201518:11:10Statement of Changes in Beneficial Ownership (4)
07/07/201514:04:49Statement of Changes in Beneficial Ownership (4)
07/07/201508:45:00Neogen signs commercialization agreement with Illumina
07/07/201506:30:00Illumina to Announce Second Quarter 2015 Financial Results on...

Illumina and other NASDAQ stock quotes are delayed by at least 20 minutes.
All other stock price and quote data is delayed by at least 15 minutes unless otherwise stated. By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions
Contact Us | Copyright 1999-2007 ADVFN PLC. | Privacy Policy | Investment Warning | Data accreditations | Investor Relations

ADVFNADVFN ItalyADVFN GermanyADVFN FranceADVFN BrazilADVFN JapanADVFN UKADVFN US noad